P2Y12抑制剂对非危急病患者在医院生存的影响:一项随机临床试验
在PubMed上查看摘要
概括
此摘要是机器生成的。在非重症COVID-19患者中,添加P2Y12抑制剂对肝素治疗没有改善无器官支持的日子. 这种组合治疗也显示出严重出血事件增加的趋势,这表明没有明显的益处.
科学领域
- 心血管医学
- 传染性疾病
- 临床试验
背景情况
- 血小板与COVID-19的发病有关,是潜在的治疗点.
- 了解抗血小板剂与抗凝血剂的作用对于优化患者的治疗结果至关重要.
研究的目的
- 在非重症住院COVID-19患者中增加P2Y12抑制剂的疗效和安全性.
- 要确定这种组合是否改善临床结果,特别是无器官支持的日子.
主要方法
- 这是一项适应性,开放性,随机的临床试验,涉及562名不危急的COVID-19患者.
- 患者接受治疗性肝激素加P2Y12抑制剂 (主要是提卡格勒) 或单独治疗性肝激素 (常规治疗).
- 主要结局是21天内没有器官支持;主要的安全结局是严重出血.
主要成果
- 在P2Y12抑制剂组 (21天) 和常规治疗组 (21天) 之间,无器官支持的日数中位数相似.
- 这项研究满足了改善无器官支持日的预规定的徒劳标准.
- 在P2Y12抑制剂组中,严重出血发生在2. 0%,而在常规治疗组中为0. 7%,没有统计学上显著的差异.
结论
- 在非重症COVID-19患者中添加P2Y12抑制剂并没有增加在无器官支持的日子里改善的几率.
- 根据目前的证据,该策略不推,因此需要仔细考虑观察到增加出血风险的趋势.
- 可能需要进一步的研究来探索特定的患者亚组或COVID-19管理中的替代抗血小板策略.
相关概念视频
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

